6ER-010 Metformin for prevention and treatment of antipsychotic induced weight gain

<h3>Background and Importance</h3> Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic induced weight gain are lacking. <h3>Aim and Objectives</h3> This study determined the most appropriate dosage and duration of metformin treatment to prevent and manage antipsychotic induced weight gain. The findings of this study can provide valuable guidance for medical experts. <h3>Material and Methods</h3> This review included all double-blind, placebo-controlled studies investigating metformin’s effectiveness in addressing antipsychotic-related weight gain. We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov for relevant studies from the inception to 2024. A random effects model was used for the meta-analysis. <h3>Results</h3> This meta-analysis including 20 studies with 1,070 patients revealed that metformin significantly surpassed placebo in attenuating weight gain in patients receiving antipsychotics. The mean weight change with metformin was −3.32 kg (95% confidence interval (CI): −4.57 to −2.07). Additionally, metformin use resulted in a noticeable decrease in body mass index (−1.24 kg/m<sup>2</sup> (95% CI: −1.70 to −0.77)). No significant differences were observed in outcomes between treatment durations of 12 and 24 weeks. Furthermore, the efficacy of metformin was not significantly different between doses of ≤1000 mg and &gt;1000 mg. <h3>Conclusion and Relevance</h3> This updated meta-analysis investigated the durations, dosages of metformin use in patients with schizophrenia experiencing antipsychotic induced weight gain. The findings highlight the need for additional large-scale research to validate our findings. <h3>References and/or Acknowledgements</h3> Reference de Silva, VA, <i>et al</i>. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis<i>. BMC Psychiatry</i>, 2016;<b>16</b>(1):341. <h3>Conflict of Interest</h3> No conflict of interest

Authors

Institutions

Publication Details

Published
2025-03-01
DOI
https://doi.org/10.1136/ejhpharm-2025-eahp.457
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

6ER-010 Metformin for prevention and treatment of antipsychotic induced weight gain

Hue-Tsi Wu, Tina Peng, DL Wang
Pharmacology and Obesity Treatment
article

6ER-010 Metformin for prevention and treatment of antipsychotic induced weight gain

Hue-Tsi Wu, Tina Peng, DL Wang
article en

Abstract

<h3>Background and Importance</h3> Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic induced weight gain are lacking. <h3>Aim and Objectives</h3> This study determined the most appropriate dosage and duration of metformin treatment to prevent and manage antipsychotic induced weight gain. The findings of this study can provide valuable guidance for medical experts. <h3>Material and Methods</h3> This review included all double-blind, placebo-controlled studies investigating metformin’s effectiveness in addressing antipsychotic-related weight gain. We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov for relevant studies from the inception to 2024. A random effects model was used for the meta-analysis. <h3>Results</h3> This meta-analysis including 20 studies with 1,070 patients revealed that metformin significantly surpassed placebo in attenuating weight gain in patients receiving antipsychotics. The mean weight change with metformin was −3.32 kg (95% confidence interval (CI): −4.57 to −2.07). Additionally, metformin use resulted in a noticeable decrease in body mass index (−1.24 kg/m<sup>2</sup> (95% CI: −1.70 to −0.77)). No significant differences were observed in outcomes between treatment durations of 12 and 24 weeks. Furthermore, the efficacy of metformin was not significantly different between doses of ≤1000 mg and &gt;1000 mg. <h3>Conclusion and Relevance</h3> This updated meta-analysis investigated the durations, dosages of metformin use in patients with schizophrenia experiencing antipsychotic induced weight gain. The findings highlight the need for additional large-scale research to validate our findings. <h3>References and/or Acknowledgements</h3> Reference de Silva, VA, <i>et al</i>. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis<i>. BMC Psychiatry</i>, 2016;<b>16</b>(1):341. <h3>Conflict of Interest</h3> No conflict of interest

Taipei Tzu Chi Hospital (TW)
Good health and well-being
Openalex Percentile: Top 94%
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.